| Product Code: ETC9205528 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Serbia Clinical Oncology Next Generation Sequencing Market Overview |
3.1 Serbia Country Macro Economic Indicators |
3.2 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, 2021 & 2031F |
3.3 Serbia Clinical Oncology Next Generation Sequencing Market - Industry Life Cycle |
3.4 Serbia Clinical Oncology Next Generation Sequencing Market - Porter's Five Forces |
3.5 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume Share, By Workflow, 2021 & 2031F |
3.7 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Serbia Clinical Oncology Next Generation Sequencing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Serbia |
4.2.2 Advancements in next-generation sequencing (NGS) technologies |
4.2.3 Growing demand for personalized medicine in oncology |
4.3 Market Restraints |
4.3.1 High costs associated with NGS testing |
4.3.2 Limited reimbursement policies for NGS in clinical oncology |
4.3.3 Lack of skilled professionals in the field of NGS in Serbia |
5 Serbia Clinical Oncology Next Generation Sequencing Market Trends |
6 Serbia Clinical Oncology Next Generation Sequencing Market, By Types |
6.1 Serbia Clinical Oncology Next Generation Sequencing Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Technology, 2021- 2031F |
6.1.3 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.1.4 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F |
6.1.5 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Targeted Sequencing, 2021- 2031F |
6.1.6 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Resequencing, 2021- 2031F |
6.2 Serbia Clinical Oncology Next Generation Sequencing Market, By Workflow |
6.2.1 Overview and Analysis |
6.2.2 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By NGS Pre-Sequencing, 2021- 2031F |
6.2.3 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By NGS Sequencing, 2021- 2031F |
6.2.4 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By NGS Data Analysis, 2021- 2031F |
6.3 Serbia Clinical Oncology Next Generation Sequencing Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Screening, 2021- 2031F |
6.3.3 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Companion Diagnostics, 2021- 2031F |
6.3.4 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Serbia Clinical Oncology Next Generation Sequencing Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Laboratories, 2021- 2031F |
6.4.5 Serbia Clinical Oncology Next Generation Sequencing Market Revenues & Volume, By Others, 2021- 2031F |
7 Serbia Clinical Oncology Next Generation Sequencing Market Import-Export Trade Statistics |
7.1 Serbia Clinical Oncology Next Generation Sequencing Market Export to Major Countries |
7.2 Serbia Clinical Oncology Next Generation Sequencing Market Imports from Major Countries |
8 Serbia Clinical Oncology Next Generation Sequencing Market Key Performance Indicators |
8.1 Average turnaround time for NGS testing in clinical oncology |
8.2 Number of clinical trials incorporating NGS technology |
8.3 Adoption rate of NGS testing in clinical oncology facilities |
9 Serbia Clinical Oncology Next Generation Sequencing Market - Opportunity Assessment |
9.1 Serbia Clinical Oncology Next Generation Sequencing Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 Serbia Clinical Oncology Next Generation Sequencing Market Opportunity Assessment, By Workflow, 2021 & 2031F |
9.3 Serbia Clinical Oncology Next Generation Sequencing Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Serbia Clinical Oncology Next Generation Sequencing Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Serbia Clinical Oncology Next Generation Sequencing Market - Competitive Landscape |
10.1 Serbia Clinical Oncology Next Generation Sequencing Market Revenue Share, By Companies, 2024 |
10.2 Serbia Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here